Menu
POTENTIAL DEAL DETAILS
| Stock | Ablynx NV | Symbol | ABLX |
| Date Announced | 01/08/2018 | Source | Reuters |
| Type | Unsolicited Bid | Acquiring Company/Person | Sanofi |
| Date of Confirmation: | 01/29/2018 | Price at Confirmation: | $53.65 |
| Potential Profit: | 38.92% | Annualized Profit: | 676.43% |
Denmark’s Novo Nordisk (NVO), the world’s biggest maker of insulin, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx (ABLX) on Monday as it seeks to bolster its treatments for rare blood disorders.
Update(s):
January 29, 2018: French drugmaker Sanofi (SNY) has agreed to buy Belgian biotech company Ablynx (ABLX) for 3.9 billion euros, beating Novo Nordisk (NVO) and marking its second big deal this month after buying Bioverativ.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.